MindRank plugs its Intera life-science foundation model into Tencent's WorkBuddy-based AI workbench, putting target discovery through clinical research in one workflow
Synopsis
MindRank and Tencent Health announced a technical collaboration at the 2026 Tencent Global Digital Ecosystem Summit to bring MindRank's in-house Intera life-science foundation model into Tencent's one-stop life-science AI workbench, built on WorkBuddy. As one of the workbench's first ecosystem partners, MindRank plans to fold Intera into drug R&D workflows spanning target discovery, molecular design, virtual screening, automated synthesis, biological testing and clinical research, adding models versed in multiple drug modalities. The two sides will also explore structured return of experimental and clinical data to build a clinical data-in-the-loop cycle that keeps iterating the models.
Interpretation
MindRank's in-house Intera life-science foundation model family will be connected to Tencent's one-stop life-science AI workbench built on WorkBuddy, with MindRank joining as one of the platform's first ecosystem partners. Intera previously addressed disease understanding, mechanism analysis, drug design and patient research across discovery, molecular design, R&D decisions and clinical research, but had not entered this Tencent platform aimed at pharma R&D teams, research institutes, universities and AI for Science companies. The collaboration was announced at the life-science session of the 2026 Tencent Global Digital Ecosystem Summit, and the receiving platform is Tencent Health's life-science AI workbench built on WorkBuddy, the all-scenario AI office agent launched in March this year.
After integration, Intera is intended to enter the platform's drug R&D workflow, linking life-science models, R&D data, computing infrastructure and real R&D settings. The platform thereby gains professional models with R&D and experimental-validation capability across small molecules, siRNA, cyclic peptides/peptides and antibodies, rather than general office-agent capability alone. The industrial links named for expansion are target discovery, molecular design, virtual screening, automated synthesis, biological testing and clinical research; MindRank also drives 30 multimodal in-house pipelines with its AI drug-discovery engine, 2 of them in clinical stage.
The two sides plan to jointly explore structured return of experimental and clinical research data, driving continuous model iteration and gradually building a clinical data-in-the-loop cycle. Model iteration input extends from single R&D tasks to the return of experimental and clinical data within the platform, a step not described for the standalone model family before. This arrangement is listed alongside model R&D, automated experimental validation, data loops and ecosystem services as areas for deeper future collaboration.
Perspective
The report covers the technical collaboration exploration announced by MindRank and Tencent Health at the life-science session of the 2026 Tencent Global Digital Ecosystem Summit: advancing Intera's integration into Tencent's life-science AI workbench and co-building AI drug-discovery infrastructure. Actual post-integration performance, participating institutions and usage scale are not given in the material.
The material describes integration and collaboration with wording such as planned and will jointly explore, without a timeline, degree of completion or any quantified effect; the RMB 1.75 billion figure in the MDR-001 deal with 3SBio is a potential total transaction value, not confirmed revenue.